Association for
Multiple Endocrine
Neoplasia Disorders

We are often contacted by researchers who are looking for patients with certain conditions to take part in different types of research projects, from surveys to clinical trials.  Please check this page regularly to see what opportunities might be available for you to get involved in and help further the search for better treatments and for cures.  For US clinical trials please visit clinicaltrials.gov.

Please discuss potential participation in clinical trials with your specialist!

Note: this list does not constitute any form of recommendation and is not a complete list.  To ensure you have all the facts, speak with your specialist.  AMEND cannot be held liable for information on external websites.

upLIFT study, phase 3 clinical trial of ersodetug for hyperinsulinism (HI)

Rezolute is a late-stage rare disease company focused on substantially improving the quality of life for individuals living with hyperinsulinism (HI) and is now enrolling participants in the upLIFT study, a phase 3 clinical trial that is testing whether or not a new therapy, called ersodetug, can safely reduce hypoglycaemia in adults with tumour HI.

In tumour HI, certain tumours (lumps or abnormal cell growths) in the pancreas or other parts of the body make too much insulin or a similar protein called insulin-like growth factor-2 (IGF-2). Insulinomas are a rare type of neuroendocrine tumour that usually form from the insulin-secreting cells in the pancreas. Non-islet cell tumour hypoglycaemia (sometimes called “Doege-Potter syndrome” or “paraneoplastic hypoglycaemia”) is a rare condition where certain tumours outside the pancreas make too much hormone growth factors that can act like insulin. Both types of tumours can lead to very low blood sugar levels, a severe and potentially life-threatening complication of overactivation of the insulin receptor.

Hypoglycaemia can result in neurologic and cognitive problems as well as other serious health complications and may make it hard for people with tumour HI to stay healthy enough to continue their cancer treatments. We know that patients facing these complications often have complex needs and limited treatment options. We believe collaboration between patient advocacy organizations is essential to ensure patients receive the best possible support and access to care.

This study is open to people 18 and older who have a type of tumour that causes tumour HI and are still experiencing frequent, serious low blood sugar levels, even with standard treatment. To learn more about the study or potential participation please talk to your doctor or visit upliftstudy.com or clinicaltrials.gov. You may also contact patient affairs via email at patient-affairs@rezolutebio.com for further assistance, if needed.

Two centres in the UK are currently offering participation in this trial to suitable candidates.  If your specialist feels that this trial may be suitable for you, they should contact colleagues at either of the following:

1. The Christie Hospital, Manchester
2. The Royal Free Hospital, London

Please note that ersodetug is still under investigation and has not been approved by any health authority.

[posted 06/01/2026]